Janssen Pharmaceutica v Pfizer Pty Ltd

Link copied
Case Copied 4 min read

IN THE FEDERAL COURT OF AUSTRALIA

) )

NEW SOUTH WALES DISTRICT REGISTRY

)

No. G.220 of 1985

)

DIVISION

GENERAL

)

JANSSEN PHARMACEUTICA

PTY. LTD.

Applicant

PFIZER PTY. LTD.

Respondent

MINUTE OF ORDER OF THE COURT

Judqe Makins Order: Burchett J.

OF AUSTRAUA L.

Date Order Made:

19 November 1985

2 8 JAN 2003

Where Made

:

Sydney

THE COIJRT ORDERS THAT:

(1) The

Respondent by'

itself

its

servants

and

agents

be

restrained from publishing

or

disseminating the video

recording entitled "Worms

- Knowledge & Treatment" ("the

video") and

the

manual

entitled

"Pfizer

Pharmacy

Reference Manual"

( "the manual"

1 and from causing

or

permitting to be broadcast the television advertisement

made on behalf of the Respondent in relation to its

product "Combantrin"

( "the

television advertisement")

and such

of the radio advertisements broadcast

on behalf

of the Respondent

as suggest expressly

or by implication

that

there

three

a

common

human-infesting

gastro-intestinal

nematode

worms

in

Australia

("the

radio advertisements").

The Respondent forthwith cause

such steps

to be taken as

may be necessary to recall and

procure to be redelivered

2.

to the Respondent all copies of the video and

so far as

may be in its power the manual which have been published

and disseminated by the Respondent within Australia and

to

prevent

the

future

broadcast

of

the

television

advertisement and the radio advertisements.

The

Respondent forthwith cause to be destroyed all

copies of the video and the manual in its possession

save for two

( 2 ) copies of the video and five

( 5 ) copies

of the manual which

it may keep €or its own record

purposes only, and forthwith upon recall

of any video or

manual

previously

disseminated

cause

such

video

or

manual to be destroyed, destruction in respect of the

video €or

the purposes of this order to include the

wiping by magnetic means of the material recorded on the

cassette tape forming part of the video.

The Respondent by itself its servants and agents be restrained from without the prior leave of the Court

publishing or making

by

any

medium

any

of

thc

representations

or

any

representations

which

are

substantially the same as the representations set out in

the Schedule to the Amended Application.

Where

a

representation in the Schedule

i s expressed

in

the

alternative this order refers to each of the alternative

versions of the representation.

(5) The Respondent

forthwith

inform

the

applicant

by

affidavit of all persons

to whom the Respondent

is aware

after all reasonable enquiry that

it has delivered or

caused t o be delivered a copy

of the video

or the manual

or either of them.

The Respondent

forthwith

cause

published

be

to

prominently in "Pharmacy Trade" and

"Australian Journal

of Pharmacy" an announcement in the

following terms:-

"IMPORTANT ANNOUNCEMENT BY PFIZEX PTY.

LIMITED

The Federal

Court of

Australia

has

ruled that Pfizer Pty. Limited

in

its

recent

advertising

and

promotion

of

Combantrin has engaged in conduct that

is misleading or

deceptive in that it

has made…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Janssen Pharmaceutica v Pfizer Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[1985] FCA 697
Decision Date

CaseChat Overview and Summary

In the Federal Court of Australia, Janssen Pharmaceutica Pty Ltd (Applicant) filed a case against Pfizer Pty Ltd (Respondent) concerning misleading and deceptive advertising practices. The Applicant alleged that the Respondent made false claims in its advertising materials for their product, Combantrin, regarding the types of human-infesting gastro-intestinal nematode worms present in Australia. Specifically, the Applicant claimed that the Respondent falsely stated that there were only three types of such worms in Australia and that threadworm, roundworm, and hookworm were common, when in fact there were at least five types of worms and only threadworm was common.

The court was required to determine whether the Respondent's advertising practices constituted misleading or deceptive conduct under the Trade Practices Act 1974 (Cth). The Applicant argued that the Respondent's statements were misleading and deceptive because they were false and likely to mislead consumers about the types of worms present in Australia and their prevalence. The Respondent, on the other hand, argued that their advertising materials did not contain any misleading or deceptive statements.

The court found in favour of the Applicant, holding that the Respondent's advertising practices constituted misleading or deceptive conduct. The court determined that the Respondent's statements were false and misleading, as there were at least five types of human-infesting gastro-intestinal nematode worms present in Australia, and only threadworm was common. The court also found that the Respondent's advertising materials were likely to mislead consumers about the types of worms present in Australia and their prevalence.

The court issued an order restraining the Respondent from publishing or disseminating the video recording entitled "Worms - Knowledge & Treatment," the manual entitled "Pfizer Pharmacy Reference Manual," and from broadcasting the television and radio advertisements made on behalf of the Respondent. The Respondent was also required to recall and destroy all copies of the video and manual that had been published and disseminated within Australia. The Respondent was further ordered to inform the Applicant of all persons to whom they had delivered or caused to be delivered a copy of the video or manual or either of them. The Respondent was also required to publish an announcement in "Pharmacy Trade" and "Australian Journal of Pharmacy" and a national daily newspaper, informing the public of the court's ruling and requesting that pharmacists cease further distribution and use of the promotional materials. The Respondent was also ordered to pay the Applicant's costs of the proceedings.

In summary, the court held that the Respondent's advertising practices constituted misleading or deceptive conduct under the Trade Practices Act 1974 (Cth) and issued an order to restrain the Respondent from further disseminating the misleading information and to take steps to recall and destroy the promotional materials.

Background

Background to the litigation

Janssen Pharmaceutica Pty. Ltd. initiated legal proceedings against Pfizer Pty. Ltd. over the latter's promotional and advertising activities for its product "Combantrin". The dispute arose from Pfizer's video recording titled "Worms - Knowledge & Treatment", a manual named "Pfizer Pharmacy Reference Manual", a television advertisement, and radio advertisements. These materials suggested that only three types of human-infesting gastro-intestinal nematode worms exist in Australia - threadworm, roundworm, and hookworm - and that these were common. Janssen argued that these claims were misleading and deceptive as there are actually at least five types of such worms in Australia, with roundworm and hookworm being extremely rare. The misleading nature of the advertisements and promotional materials led to Janssen seeking an injunction against Pfizer.

The case was heard in the Federal Court of Australia, New South Wales District Registry. Janssen Pharmaceutica Pty. Ltd. was the applicant and Pfizer Pty. Ltd. was the respondent. The matter was brought before the court seeking injunctive relief and damages. The court heard evidence and submissions from both parties, and subsequently delivered its judgment and orders.

Decision

Reasons for decision

Issues
1. Whether Pfizer Pty. Ltd. engaged in conduct that was misleading or deceptive in its advertising and promotional materials for "Combantrin".
2. Whether an injunction should be granted to restrain Pfizer Pty. Ltd. from disseminating or broadcasting the contested promotional materials.
3. What form of corrective advertising or public announcements Pfizer Pty. Ltd. should be required to undertake to rectify the misleading statements.
4. Whether Pfizer Pty. Ltd. should be ordered to pay Janssen Pharmaceutica Pty. Ltd.'s costs of the proceedings.

Held
1. The Court concluded that Pfizer Pty. Ltd. engaged in conduct that was misleading or deceptive in its advertising and promotional materials for "Combantrin".
2. The Court granted an injunction to restrain Pfizer Pty. Ltd. from disseminating or broadcasting the contested promotional materials.
3. The Court required Pfizer Pty. Ltd. to undertake specified forms of corrective advertising and public announcements to rectify the misleading statements.
4. The Court ordered Pfizer Pty. Ltd. to pay Janssen Pharmaceutica Pty. Ltd.'s costs of the proceedings.

Ratio Decidendi

Legal Principle Established

The Federal Court examined the advertising and promotional materials produced by Pfizer Pty. Ltd. for their product "Combantrin" and found that these materials contained statements and representations that were misleading or deceptive. The Court identified two key areas of misleading conduct: first, the claim that there were only three types of human-infesting gastro-intestinal nematode worms in Australia, when in fact there are at least five such types; and second, the assertion that threadworm, roundworm, and hookworm are common in Australia, when in reality only threadworm is common and roundworm and hookworm are extremely rare. The Court relied on evidence presented by Janssen Pharmaceutica Pty. Ltd. to substantiate these claims of misleading conduct. In granting an injunction, the Court aimed to prevent further dissemination of the misleading materials and to ensure compliance with the corrective measures. The Court ordered Pfizer Pty. Ltd. to recall and destroy all copies of the promotional materials, cease broadcasting the contested advertisements, and publish corrective announcements in specified professional and national media outlets. This was intended to rectify the misleading information and inform the public and industry stakeholders of the Court's findings. Finally, the Court ordered Pfizer Pty. Ltd. to pay Janssen Pharmaceutica Pty. Ltd.'s costs of the proceedings, reflecting the legal principle that the losing party in proceedings of this nature may be required to compensate the successful party for the costs incurred.